EMA Authorised: HBVaxPro (hepatitis B, recombinant surface antigen) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA authorised HBVaxPro, a recombinant hepatitis B surface antigen vaccine, for immunization against hepatitis B in the European Union. The product is manufactu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• HBVaxPro (Hepatitis B surface antigen, recombinant)

Snippet

Status: Authorised. Therapeutic area: Hepatitis B;Immunization. MAH: Merck Sharp & Dohme B.V.. Decision date: 07/11/2025